Randomized Open-Label Phase II Trial of Apitolisib...

Journal of Clinical Oncology 2016 / 03

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

Powles, T., Lackner, M. R., Oudard, S., Escudier, B., Ralph, C., Brown, J. E., Hawkins, R. E., Castellano, D., Rini, B. I., Staehler, M. D., Ravaud, A., Lin, W., OKeeffe, B., Wang, Y., Lu, S., Spoerke
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2015.64.8808
Date:
March, 2016
File:
PDF, 1.49 MB
english, 2016
Conversion to is in progress
Conversion to is failed